Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw784752X SCHEMBL29534241 | 1.00 | GSK3B (1.00) | GSK3BGSK3A | |
| SCHEMBL8339760 | 0.92 | GSK3B (1.00) | GSK3BGSK3A | |
| SCHEMBL8344607 | 0.91 | GSK3B (0.84) | GSK3BGSK3A | |
| SCHEMBL8343169 | 0.90 | GSK3B (0.82) | GSK3BGSK3A | |
| SCHEMBL8342451 | 0.90 | GSK3B (0.82) | GSK3BGSK3A | |
| SCHEMBL8342769 | 0.90 | GSK3B (1.00) | GSK3BGSK3A | |
| SCHEMBL8344429 | 0.90 | GSK3B (1.00) | GSK3BGSK3A | |
| SCHEMBL8344464 | 0.89 | GSK3B (1.00) | GSK3BGSK3A | |
| SCHEMBL8339151 | 0.89 | GSK3B (0.81) | GSK3BGSK3A | |
| SCHEMBL8344582 | 0.89 | GSK3B (0.89) | GSK3BGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024497-A1 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes | ALNYLAM PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024497-A1 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes | ALNYLAM PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9029525-B2 | Compositions and methods for inhibiting expression of GSK-3 genes | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029525-B2 | Compositions and methods for inhibiting expression of GSK-3 genes | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20110184046-A1 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes | ALNYLAM PHARMACEUTICALS, INC. | 2011-07-28 | — | — | US | disclosed |
| WO-2004009602-A1 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184046-A1 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes | GSK3A, GSK3B, GSKIP | GSK3B 2/4885GSK3A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.